That is what I said , it is a general condition of such conferences otherwise there would be no reason to spend thousands on a junket to attend if you could see it published elsewhere first before conference , and qualified it that no problems with that but to suggest content is just not on IMO. Attendees can access at 4th October ( not data) but shareholders can't - yes it is very early stage but .........
I did a quick look for conditions of acceptance of abstracts / posters but didn't find it to prove embargo but it is usual at most industry conferences.
I just want to hilight the timing here Why has SPL only just told shareholders?
https://www.aacr.org/meeting/aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics-2/abstracts/
"Abstract titles and presenters (no data) will be available on the AACR website in mid-September.
All accepted regular abstracts (submitted for the July 10 deadline) are scheduled to be released to registrants in the conference app at 12:00 pm U.S. ET, on Wednesday, October 4, 2023, with the exception of abstracts selected for inclusion in the AACR press program.
All accepted late-breaking abstracts (submitted for the August 30 deadline) are scheduled to be released to registrants via the conference app at 12:00 pm U.S. ET, on Wednesday, October 11, 2023, , with the exception of abstracts selected for inclusion in the AACR press program.
Any abstract selected for the official meeting press program will be posted during the conference at the beginning of the session where the study is being presented.
"
so at least 7? days ago poster titles were already in listing and most were mid September - SPL must have the worlds slowest email confirmation of poster acceptance?????
Poster presentations (as of 9/18/23)
poster
A147: A HER2 targeted polylysine dendrimer nanoparticle radiotheranostic demonstrates excellent tumoraccumulation, rapid clearance from circulation, and promising performance in PET-CT imaging. JeremyR.A. Paull, Starpharma Pty Ltd, Melbourne, Australia
Poster presentations (as of 9/19/23)
poster
B039: A phase 1/2 study of dendrimer-enhanced (DEP) SN38 (SN38-SPL9111 / DEP irinotecan) inpatients with advanced solid tumours. Jia Liu, The Kinghorn Cancer Centre, St Vincent’s Hospital; GarvanInstitute of Medical Research; St Vincent’s Clinical School, University of New South Wales, Sydney,Australia.
Poster presentations (as of 9/19/23)
Poster
C167: An SN38 dendrimer nanoparticle, DEP irinotecan (SN38-SPL9111), demonstrates efficacy inmouse models of gastrointestinal cancer and augments anti-tumor effects of immune checkpointblockade and PARP inhibition. Jeremy R.A. Paull, Starpharma Pty Ltd, Melbourne, Australia.
https://www.aacr.org/meeting/aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics-2/
$00-1200 to attend plus all accomodation etc etc and othe revents
Conference Cochairs
Timothy A. Yap, The University of Texas MD Anderson Cancer Center, Houston, Texas (AACR)
Tim F. Greten, National Cancer Institute, Bethesda, Maryland (NCI)
E.G. Elisabeth de Vries, University Medical Centre Gronigen, Gronigen, Netherlands (EORTC)
Hosted by the American Association for Cancer Research, the National Cancer Institute, and the European Organisation for Research and Treatment of Cancer, the 2023 Molecular Targets and Cancer Therapeutics conference will return to the Hynes Convention Center in Boston. This program attracts 1,200-1,500 academics, scientists, and pharmaceutical industry representatives from across the globe to discuss innovations in drug development, target selection, the impact of new discoveries in cellular and molecular biology, and early clinical trials. Innovative, targeted therapeutics are discovered through the rapid advances in our understanding of the molecular basis of cancer. Continued clinical progress in cancer treatments is accomplished through the conduct of translational research projects, efficient new drug development, and the execution of large, prospective, randomized, multicenter cancer clinical trials. This requires a joint and global approach to exchange information early in the development process.
Conference CochairsTimothy A. Yap, The University of Texas MD Anderson Cancer Center, Houston, Texas (AACR)Tim F. Greten, National Cancer Institute, Bethesda, Maryland (NCI)E.G. Elisabeth de Vries, University Medical Centre Gronigen, Gronigen, Netherlands (EORTC)Hosted by the American Association for Cancer Research, the National Cancer Institute, and the European Organisation for Research and Treatment of Cancer, the 2023 Molecular Targets and Cancer Therapeutics conference will return to the Hynes Convention Center in Boston. This program attracts 1,200-1,500 academics, scientists, and pharmaceutical industry representatives from across the globe to discuss innovations in drug development, target selection, the impact of new discoveries in cellular and molecular biology, and early clinical trials. Innovative, targeted therapeutics are discovered through the rapid advances in our understanding of the molecular basis of cancer. Continued clinical progress in cancer treatments is accomplished through the conduct of translational research projects, efficient new drug development, and the execution of large, prospective, randomized, multicenter cancer clinical trials. This requires a joint and global approach to exchange information early in the development process.
(20min delay)